PMID- 31956621
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220412
IS  - 2278-330X (Print)
IS  - 2278-4306 (Electronic)
IS  - 2278-330X (Linking)
VI  - 9
IP  - 1
DP  - 2020 Jan-Mar
TI  - Nimotuzumab with intensity-modulated radiation therapy in unresectable and 
      platinum-ineligible locally advanced head-and-neck cancer.
PG  - 43-46
LID - 10.4103/sajc.sajc_29_19 [doi]
AB  - BACKGROUND: Outcomes with conventional treatment are poor in patients with 
      squamous cell carcinoma of head and neck (SCCHN). Treatment options are further 
      limited for patients ineligible to receive platinum-based chemotherapy due to 
      various factors such as geriatric age, comorbidity, and organ dysfunctions. The 
      present study retrospectively evaluated the effectiveness of nimotuzumab when 
      added to radiation therapy in unresectable, locally advanced SCCHN patients who 
      were ineligible for platinum-based chemotherapy. MATERIALS AND METHODS: The 
      medical records of 21 patients with unresectable, locally advanced head-and-neck 
      cancer and histologically confirmed squamous cell carcinoma who were ineligible 
      for platinum-based chemotherapy treated with nimotuzumab and intensity-modulated 
      radiation therapy (IMRT) from 2012 to 2017 were retrospectively analyzed. The 
      tumor response rate and overall survival (OS) were analyzed. Patients were 
      assessed for toxicity and adverse events (AEs) as per CTCAE version 4. 
      Statistical analysis was performed using SPSS software. RESULTS: The median 
      number of doses of nimotuzumab received was 6, and median dose of radiotherapy 
      was 60 Gy. The tumor response rate was calculated at 24 weeks after the 
      completion of radiotherapy and was as follows: 76.2% (16) of patients showed 
      complete response, 9.5% (2) of patients showed partial response, 4.8% (1) of 
      patients showed stable disease, and 9.5% (2) of patients showed progression of 
      disease. Median OS was 21 months, whereas 1-year survival rate was 63.7%. No 
      Grade 3 or Grade 4 AEs were observed. CONCLUSION: Nimotuzumab with IMRT has 
      achieved promising clinical outcomes in unresectable locally advanced SCCHN 
      patients who are ineligible for platinum-based chemotherapy, without accumulation 
      of toxicity.
CI  - Copyright: (c) 2019 The South Asian Journal of Cancer.
FAU - Srinivas, K Satish
AU  - Srinivas KS
AD  - Department of Radiation Oncology, Sri Ramachandra Medical College, Sri 
      Ramachandra Institute of Higher Education and Research (DU), Chennai, Tamil Nadu, 
      India.
FAU - Sundaram, Raja
AU  - Sundaram R
AD  - Department of Radiation Oncology, Global Institute of Oncology, Gleneagles Global 
      Health City, Chennai, Tamil Nadu, India.
FAU - Divyambika, C V
AU  - Divyambika CV
AD  - Department of Oral Medicine and Radiology, Faculty of Dental Sciences, Sri 
      Ramachandra Institute of Higher Education and Research (DU), Chennai, Tamil Nadu, 
      India.
FAU - Chaudhari, Sameer
AU  - Chaudhari S
AD  - Medical Advisor, Biocon Ltd., Bengaluru, Karnataka, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - South Asian J Cancer
JT  - South Asian journal of cancer
JID - 101618774
PMC - PMC6956585
OTO - NOTNLM
OT  - Advanced
OT  - antibodies
OT  - carcinoma
OT  - head-and-neck neoplasms
OT  - inoperable
OT  - monoclonal
OT  - nimotuzumab
OT  - overall survival
OT  - platinum ineligible
OT  - squamous cell
OT  - therapy
COIS- There are no conflicts of interest.
EDAT- 2020/01/21 06:00
MHDA- 2020/01/21 06:01
PMCR- 2020/01/01
CRDT- 2020/01/21 06:00
PHST- 2020/01/21 06:00 [entrez]
PHST- 2020/01/21 06:00 [pubmed]
PHST- 2020/01/21 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - SAJC-9-43 [pii]
AID - 10.4103/sajc.sajc_29_19 [doi]
PST - ppublish
SO  - South Asian J Cancer. 2020 Jan-Mar;9(1):43-46. doi: 10.4103/sajc.sajc_29_19.